A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants

NCT ID: NCT04243083

Last Updated: 2021-03-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-26
• Study Completion Date: 2021-01-31

Brief Summary

TLL018 is developed for treatment of autoimmune and inflammatory diseases including rheumatoid arthritis. The purposes of this study are (1) determining if and at what doses TLL018 is safe and can be tolerated when administered to humans, (2) assessing what TLL018 does to the body and how the body responds to TLL018 when given as single and multiple doses, and (3) assessing potential food effect on TLL018.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Single Ascending Dose (SAD)

There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.

Group Type: EXPERIMENTAL

TLL018 tablet, placebo

Intervention Type: DRUG

Oral QD

Multiple Ascending Dose (MAD)

There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.

Group Type: EXPERIMENTAL

TLL018 tablet, placebo

Intervention Type: DRUG

Oral QD

Food Effect Panel

Twelve subjects will receive a single dose of TLL018 in 2 treatment periods, one after a high fat, high calorie breakfast (fed) and the second treatment period under fasted conditions to determine the effect of food on the PK of TLL018.

Group Type: EXPERIMENTAL

TLL018 tablet, placebo

Intervention Type: DRUG

Oral QD

Interventions

TLL018 tablet, placebo

Oral QD

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Are capable of giving informed consent and complying with study procedures;

2. Are between the ages of 18 and 55 years, inclusive;

3. Female subjects have a negative serum hCG or urine pregnancy test result at screening and Day -1, and meet one of the following criteria:

1. Using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives) [e.g., hormonal contraceptives (oral, patch, injectable or vaginal ring), implantable device (implantable rod or intrauterine device), or a double barrier (e.g., diaphragm, cervical cap, oral, patch or vaginal hormonal contraceptive, condom, spermicide, or sponge)]

2. Surgically sterile, with documentation, for at least 3 months prior to screening by one of the following means:

• Bilateral tubal ligation
• Bilateral salpingectomy (with or without oophorectomy)
• Surgical hysterectomy
• Bilateral oophorectomy (with or without hysterectomy)

3. Postmenopausal, defined as the following:

• Last menstrual period greater than 12 months prior to screening
• Postmenopausal status confirmed by serum follicle stimulating hormone (FSH) and estradiol levels at screening;

4. Considered healthy by the Investigator, based on subject's reported medical history, full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs;

5. Normal renal function as determined by Investigator following review of clinical laboratory test results;

6. Non-smoker or no more than 2 tobacco-containing including nicotine replacement products in last 6 months;

7. Body mass index (BMI) of 18.0 to 30.0 kg/m2 inclusive and body weight not less than 50 kg; Subjects with BMI between 30 and 32 kg/m2 may be allowed to participate with the sponsor's approval;

8. Willing and able to adhere to study restrictions and to be confined at the clinical research center;

9. Male subjects with female partners of child-bearing potential must agree to use condoms for the duration of the study and until 12 weeks after dosing with the study drug and must refrain from donating sperm for this same period;

10. Ability to swallow and retain oral medication.

Exclusion Criteria

1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the Investigator;

2. Pregnant (as determined by pregnancy test result) and breastfeeding women;

3. Current and/or recent history (<30 days prior to screening and/or <45 days prior to randomization) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection;

4. Current clinically significant viral infection;

5. Evidence of latent or active tuberculosis, as well as recent exposure or live vaccinations

6. History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin;

7. History of pancreatitis or gall stones;

8. History of unexplained syncope, symptomatic hypotension or hypoglycemia;

9. Family history of long QTc syndrome; History or presence of an abnormal ECG, which, in the investigator's opinion, is clinically significant. QTcF interval >440 msec for males and >460 msec for females;

10. Resting pulse <45 bpm or >100 bpm at screening, only with Day -1 as PI judgement;

11. History of unstable ischemic heart disease or uncontrolled hypertension (blood pressure >140/90 mm Hg at screening, only with Day -1 as PI judgement);

12. History of stomach or intestinal surgery, except that appendectomy and/or cholecystectomy will be allowed;

13. History of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or intolerance;

14. Poor venous access;

15. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody;

16. Donated or lost >500 ml of blood in the previous 3 months;

17. Taken any prescription medications within 7 days or 5 half-lives (whichever is longer) of the first dose of study drug;

18. Hospital admission or major surgery within 6 months prior to screening;

19. A history of prescription drug abuse, or illicit drug use within 9 months prior to screening;

20. A history of alcohol abuse according to medical history within 9 months prior to screening;

21. A positive screen for alcohol or drugs of abuse at screening or Day -1;

22. An unwillingness or inability to comply with food and beverage restrictions during study participation;

23. Use of over-the-counter (OTC) medication within 7 days, and herbal (including St John's Wort, herbal teas, garlic extracts) within 7 days prior to dosing (Note: Use of acetaminophen at <2 g/day is permitted until 24 hours prior to dosing);

24. Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study medication with another investigational medication or current enrollment in another investigational drug protocol;

25. Hemoglobin, WBC, or platelet count below the lower reference limit of the testing laboratory. Absolute neutrophil count <2000 cells/uL;

26. Any condition or finding that in the Investigators opinion would put the subject or study conduct at risk if the subject were to participate in the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

TLL Pharmaceutical, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Frank Lee, MD

Role: STUDY_DIRECTOR

Frontage Clinical Services

Locations

Frontage Clinical Services, Inc.

Secaucus, New Jersey, United States

Countries

United States

Other Identifiers

TLL018-101

Identifier Type: -

Identifier Source: org_study_id